XENEXenon Pharmaceuticals Inc.
$35.82-4.1% 1Y
$35.82
$35.8252 weeks$68.91
Latest close: a new 52-week lowOct 12, 2026what changed →
XENE in its own filings
XENE's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
226
Events found in the filings · across 798 filings · the record starts in 2013
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 12, 2013
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- Restatement admitted (non-reliance)historical
- 2015-08-13
- Change in certifying accountantpast_3y
- 2025-03-05
- SEC comment-letter activity18 occurrences
- 2020-06-10
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Xenon Reports Q2 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 7, 2026Xenon Reports Q1 2026 Financial Results and Provides Business Update.Earnings release · press release
- Apr 13, 2026On April 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) amended and restated the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement …Director or officer change · Form 8-K
- Mar 13, 2026On March 13, 2026, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.Other event · Form 8-K
- Mar 12, 2026The information set forth below in.Material agreement entered · Form 8-K
- Mar 9, 2026Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner.Regulation FD disclosure · press release
- Feb 27, 2026On February 27, 2026, Xenon Pharmaceuticals Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “SEC”) to register $400,000,000 of common shares, without par value (the “Shares”) issuable pursuant to the at-the-market equity offering sales …Other event · Form 8-K
- Feb 26, 2026Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Dec 1, 2025On November 24, 2025, Xenon Pharmaceuticals Inc. (the “Company”) amended and restated the Company’s 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from 775,000 …Director or officer change · Form 8-K
- Nov 3, 2025Xenon Reports Third Quarter 2025 Financial Results & Business Update.Earnings release · press release
- Oct 17, 2025On October 16, 2025, Xenon Pharmaceuticals Inc. (the “Company”) announced that Thomas (Tucker) Kelly has been appointed to serve as the Company’s Chief Financial Officer, effective October 15, 2025.Director or officer change · Form 8-K/A
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…